Capricor Therapeutics (CAPR) CFO Bergmann Sells 500 Shares

On June 22, 2026, Anthony Bergmann, the Chief Financial Officer of Capricor Therapeutics, Inc. (NASDAQ:CAPR), sold 500 shares of the company at an average price of $30 per share. This transaction was valued at $15,000 and was not part of a pre-planned trading program.

Insider Buying and Selling at Capricor Therapeutics, Inc.

Anthony Bergmann, Capricor's CFO, sold 500 shares on June 22, 2026, at $30 each, totaling $15,000. This transaction was conducted outside of a 10b5-1 trading plan. Additionally, on June 24, 2026, Bergmann sold another 400 shares, while EVP and General Counsel Karen Krasney sold 400 shares at the same price. Krasney also purchased 400 shares at $3.18 on the same day.

Other Institutional Activity in Capricor Therapeutics

Suvretta Capital Management, LLC significantly increased its stake in Capricor by 2,032,990 shares, bringing its total to 3,818,600 shares valued at about $116.1 million, a 113.9% increase. BlackRock, Inc. also boosted its holdings by 570,837 shares, now owning 3,421,815 shares worth approximately $104 million, marking a 20% increase. Tang Capital Management LLC doubled its position, adding 1,699,900 shares to hold a total of 3,399,900 shares valued at about $103.4 million. State Street Corp saw a 163% increase in its stake, adding 1,352,380 shares to reach 2,181,901 shares valued at $66.3 million. Meanwhile, Vanguard Capital Management LLC opened a new position with 2,027,732 shares worth about $61.6 million.

Capricor Therapeutics, Inc. Stock Up 225.7%

Shares of Capricor Therapeutics traded near $29.60 on Thursday. The company has a market capitalization of approximately $1.7 billion and a forward P/E ratio that is not meaningful due to negative earnings per share. Capricor's beta is 0.368, indicating lower volatility compared to the broader market. The stock's 52-week range is between $4.30 and $40.37, with a 50-day moving average of $30.58 and a 200-day moving average of $21.38. The company's financial health appears strong with a current ratio of 8.416 and a quick ratio of 8.283, though its debt-to-equity ratio is 5.305.

Analysts Set New Price Targets

On March 13, 2026, B. Riley Securities maintained its buy rating for Capricor with a price target of $63. Piper Sandler also reiterated its buy rating with a target of $58 on the same day. Earlier, on March 10, HC Wainwright & Co. reiterated a buy rating with a $60 price target. The consensus among analysts is a strong buy, with a mean price target of $54.11 based on nine opinions.

About Capricor Therapeutics

Capricor Therapeutics, Inc. is a biotechnology company based in San Diego, California. It focuses on developing innovative cell and exosome-based therapies for Duchenne muscular dystrophy and other diseases with unmet medical needs. The company's lead product, Deramiocel, is in Phase 3 clinical trials for treating Duchenne muscular dystrophy. Capricor is also working on an exosome-based vaccine for SARS-CoV-2 and other therapeutic applications. Founded in 2005, the company is led by CEO Dr. Linda Marbán and employs 231 people.

Bottom Line

The recent insider sale by Capricor's CFO, Anthony Bergmann, is one of several transactions involving company insiders. Investors often track these activities for insights, but it's important to remember that insider selling can occur for many reasons. Capricor's stock performance and institutional interest suggest ongoing market interest. As with all 13F filings, the data is historical and may not reflect current holdings.